FORM PTO-1449(Modified)	ATTY. DOCKET NO.: B0801/7169	SERIAL NO.: 09/540,024
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Tzianabos et al.	
	FILING DATE: March 31, 2000	GROUP: 1623

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes	Translation No
SWL	B4	DE 3704389 A1	25 Aug 88	Blutspendedienst DT Rote Kreuz				

OTHER ART
(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

SWL	C38		Perumal VK et al., *Clinical Research* 38(2):550A (1990).
SWL	C39		Kalka-Moll WM et al., *Abstracts of the 98th Gen. Mtg. of the Amer. Soc. for Microbiol.* 98:123 (1998).
SWL	C40		Tzianabos A et al., *Abstracts of the 99th Gen. Mtg. of the Amer. Soc. for Microbiol.* 99:37-38 (1999).
SWL	C41		PCT International Search Report for PCT/US00/08586

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

EXAMINER	DATE CONSIDERED
	6-19-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO.: **B0801/7169**	SERIAL NO : **09/540,024**
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Tzianabos et al.	
	FILING DATE: March 31, 2000	GROUP: Unknown

TECH CENTER 1600

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
SWL	A1	3,849,550	11/19/74	Teitelbaum et al.	424	78	
SWL	A2	4,619,995	10/28/86	Hayes	536	20	
SWL	A3	4,819,617	04/11/89	Goldberg et al.	128	897	
SWL	A4	4,886,787	12/12/89	de Belder et al.	514	57	
SWL	A5	4,937,270	06/26/90	Hamilton et al.	514	7.1	
SWL	A6	5,140,016	08/18/92	Goldberg et al.	514	57	
SWL	A7	5,605,938	02/25/97	Roufa et al.	514	59	
SWL	A8	5,679,654	10/21/97	Tzianabos et al.	514	54	
SWL	A9	5,679,658	10/21/97	Elson	514	55	
SWL	A10	5,700,787	12/23/97	Tzianabos et al.	514	54	
SWL	A11	5,705,178	01/06/98	Roufa et al.	424	422	
SWL	A12	5,760,200	06/02/98	Miller et al.	536	21	

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes	Translation No
SWL	B1	WO 95/31990	11/30/95	PCT	A61K	31/74		
SWL	B2	WO 96/07427	03/14/96	PCT	A61K	39/02		
SWL	B3	WO 96/32119	10/17/96	PCT	A61K	31/785		

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

SWL	C1		Aharoni R et al., Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. *J Neuroimmunol* 1998 Nov 2;91(1-2):135-46.
SWL	C2		Aharoni R et al., Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci U S A* 1997 Sep 30;94(20):10821-6.
SWL	C3		Aharoni R et al., Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. *Immunol Lett* 1997 Jul;58(2):79-87.
SWL	C4		Arnon R et al., New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. *J Neurol* 1996 Apr;243(4 Suppl 1):S8-13.
SWL	C5		Baumann H et al., Structural elucidation of two capsular polysaccharides from one strain of Bacteroides fragilis using high-resolution NMR spectroscopy. *Biochemistry* 1992 Apr 28;31(16):4081-9.
SWL	C6		Fridkis-Hareli M et al., Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. *J Immunol* 1999 Apr 15;162(8):4697-704.
SWL	C7		Fridkis-Hareli M et al., Binding of random copolymers of three amino acids to class II MHC molecules. *Int Immunol* 1999 May;11(5):635-41.
SWL	C8		Fridkis-Hareli M et al., Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. *Proc Natl Acad Sci U S A* 1994 May 24;91(11):4872-6.
SWL	C9		Fridkis-Hareli M et al., Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells. *Cell Immunol* 1995 Jul;163(2):229-36.

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: B0801/7169	SERIAL NO.: 09/540,024
	APPLICANT: Tzianabos et al.	
	FILING DATE: March 31, 2000	GROUP: Unknown

SWL	C10		Gibson FC 3rd et al., Cellular mechanism of intraabdominal abscess formation by Bacteroides fragilis. *J Immunol* 1998 May 15;160(10):5000-6.
SWL	C11		Gibson FC 3rd et al., The capsular polysaccharide complex of Bacteroides fragilis induces cytokine production from human and murine phagocytic cells. *Infect Immun* 1996 Mar;64(3):1065-9.
SWL	C12		Kalka-Moll WM et al., Effect of molecular size on the ability of zwitterionic polysaccharides to stimulate cellular immunity. *J Immunol* 2000 Jan 15;164(2):719-24.
SWL	C13		Kato T et al., Interleukin 10 reduces mortality from severe peritonitis in mice. *Antimicrob Agents Chemother* 1995 Jun;39(6):1336-40.
SWL	C14		Kennedy R et al., Prevention of experimental postoperative peritoneal adhesions byN,O-carboxymethyl chitosan. *Surgery* 1996 Nov;120(5):866-70.
SWL	C15		Krause TJ et al., An inhibitor of cell proliferation associated with adhesion formation is suppressed by N,O-carboxymethyl chitosan. *J Invest Surg* 1998 Mar-Apr;11(2):105-13.
SWL	C16		Montz FJ et al., Interleukin-10: ability to minimize postoperative intraperitoneal adhesion formation in a murine model. *Fertil Steril* 1994 Jun;61(6):1136-40.
SWL	C17		Pantosti A et al., Bacteroides fragilis strains express multiple capsular polysaccharides. *J Clin Microbiol* 1993 Jul;31(7):1850-5.
SWL	C18		Pantosti A et al., Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis. *Infect Immun* 1991 Jun;59(6):2075-82.
SWL	C19		Pavliak V et al., Structural elucidation of the capsular polysaccharide of Bacteroides fragilis strain 23745M1. *Carbohydr Res* 1995 Oct 2;275(2):333-41.
SWL	C20		Schlegel PG et al., A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. *Proc Natl Acad Sci U S A* 1996 May 14;93(10):5061-6.
SWL	C21		Teitelbaum D et al., Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. *Proc Natl Acad Sci U S A* 1999 Mar 30;96(7):3842-7.
SWL	C22		Teitelbaum D et al., Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. *Proc Natl Acad Sci U S A* 1988 Dec;85(24):9724-8.
SWL	C23		Teitelbaum D et al., Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. *Proc Natl Acad Sci U S A* 1992 Jan 1;89(1):137-41.
SWL	C24		Teitelbaum D et al., Unprimed spleen cell populations recognize macrophage-bound antigen with opposite net electric charge. *Proc Natl Acad Sci U S A* 1977 Apr;74(4):1693-6.
SWL	C25		Tzianabos AO et al., Bacterial structure and functional relation to abscess formation. *Infect Agents Dis* 1994 3:256-65.
SWL	C26		Tzianabos AO et al., Effect of surgical adhesion reduction devices on the propagation of experimental intra-abdominal infection. *Arch Surg* 1999 Nov;134(11):1254-9.
SWL	C27		Tzianabos AO et al., IL-2 mediates protection against abscess formation in an experimental model of sepsis. *J Immunol* 1999 Jul 15;163(2):893-7.
SWL	C28		Tzianabos AO et al., Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. *J Clin Invest* 1995 Dec;96(6):2727-31.
SWL	C29		Tzianabos AO et al., Protection against experimental intraabdominal sepsis by two polysaccharide immunomodulators. *J Infect Dis* 1998 Jul;178(1):200-6.
SWL	C30		Tzianabos AO et al., Structural characteristics of polysaccharides that induce protection against intra-abdominal abscess formation. *Infect Immun* 1994 Nov;62(11):4881-6.
SWL	C31		Tzianabos AO et al., Structural features of polysaccharides that induce intra-abdominal abscesses. *Science* 1993 Oct 15;262(5132):416-9.
SWL	C32		Tzianabos AO et al., Structure and function of Bacteroides fragilis capsular polysaccharides: relationship to induction and prevention of abscesses. *Clin Infect Dis* 1995 Jun;20 Suppl 2:S132-40.
SWL	C33		Tzianabos AO et al., Structure-function relationships for polysaccharide-induced intra-abdominal abscesses. *Infect Immun* 1994 Aug;62(8):3590-3.
SWL	C34		Tzianabos AO et al., T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. *J Biol Chem* 2000 Mar 10;275(10):6733-40.

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: **B0801/7169**	SERIAL NO.: **09/540,024**
	APPLICANT: Tzianabos et al.	
	FILING DATE: March 31, 2000	GROUP: Unknown

SWL	C35		Tzianabos AO et al., The capsular polysaccharide of Bacteroides fragilis comprises two ionically linked polysaccharides. *J Biol Chem* 1992 Sep 5;267(25):18230-5.
SWL	C36		Wujek JR et al., A carbohydrate polymer that effectively prevents epidural fibrosis at laminectomy sites in the rat. *Exp Neurol* 1991 Nov;114(2):237-45.
SWL	C37		Yokoyama M et al., Adhesion behavior of rat lymphocytes to poly(ether)-poly(amino acid) block and graft copolymers. *J Biomed Mater Res* 1986 Sep;20(7):867-78.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

EXAMINER	DATE CONSIDERED
	6-19-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.